PRCT 69.60 PROCEPT BioRobotics Corporation
| Range: | 24.83-85.81 | Vol Avg: | 705304 | Last Div: | 0 | Changes: | -0.61 |
| Beta: | 1.03 | Cap: | 3.72B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 15 2021 | Empoloyees: | 626 | ||
| CUSIP: | 74276L105 | CIK: | 0001588978 | ISIN: | US74276L1052 | Country: | US |
| CEO: | Dr. Reza Zadno Ph.D. | Website: | https://www.procept-biorobotics.com | ||||
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Stock Details
PRCT 95
Procept BioRobotics price target raised to $95 from $74 at Truist
Richard Newitter·Tue Sep 03 2024
Truist Financial
PRCT 79
Procept BioRobotics price target raised to $79 from $72 at Truist
Richard Newitter·Tue Jul 16 2024
Truist Financial
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow